Amelie Vogt et al.: Medical Advances in Hepatitis D Therapy: Molecular Targets. In: International Journal of Molecular Sciences. Band23, Nr.18, 16. September 2022, S.10817, doi:10.3390/ijms231810817, PMID 36142728, PMC 9506394 (freier Volltext) – (englisch).
nih.gov
ncbi.nlm.nih.gov
ES Daar, XL Li, T Moudgil, DD. Ho: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. In: Proc Natl Acad Sci USA, 1990, 87, S. 6574–6578. PMID 2395859
DR Kuritzkes, J Jacobson, WG Powderly et al.: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. In: J Infect Dis, 2004, 189, S. 286–291. PMID 14722894.
RI Connor, KE Sheridan, D Ceradini, S Choe, NR. Landau: Change in coreceptor use coreceptor use correlates with disease progression in HIV-1--infected individuals. In: J Exp Med, 1997, 185, S. 621–628. PMID 9034141
M Westby, M Lewis, J Whitcomb et al.: Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. In: J Virol, 2006, 80, S. 4909–4920, PMID 16641282.
Amelie Vogt et al.: Medical Advances in Hepatitis D Therapy: Molecular Targets. In: International Journal of Molecular Sciences. Band23, Nr.18, 16. September 2022, S.10817, doi:10.3390/ijms231810817, PMID 36142728, PMC 9506394 (freier Volltext) – (englisch).
